Hemoglobinopathies Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Hemoglobinopathies Treatment Market is Segmented by Treatment (Stem Cell Therapy, Blood Transfusion, Iron Chelation Therapy, Others), by Application, and Geography

Hemoglobinopathies Treatment Market Snapshot

Hemoglobinopathies Treatment Market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7 %
Hemoglobinopathies Treatment Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global hemoglobinopathies treatment market was studied and projected to grow with a CAGR of nearly 7% over the forecast period. The growth is primarily due to an increase in the cases of hemoglobinopathies, coupled with growing awareness pertaining to hemoglobin disorders. According to the World Health Organization, about 1.1% of the couples globally are at the risk of having a child with hemoglobin disorder and prevalence was estimated at 2.55 per 1000. In addition, the presence of strong product pipeline for the treatment of hemoglobinopathies and continuous efforts from the market players and government in developing the new therapies for the same are anticipated to boost the market growth. However, low awareness related to the hemoglobinopathies in low and some of the middle-income countries is anticipated to hamper the market growth. Moreover, the initiatives such as newborn screening for detection of potential disorders are lead by the government and private organizations are anticipated to fuel the market growth for hemoglobinopathies treatment.

Scope of the Report

As per the scope of the report, hemoglobinopathies is the group of blood disorders which are inheritable, including thalassemia, sickle cell anaemia and others.

By Treatment
Stem Cell Therapy
Blood Transfusion
Iron Chelation Therapy
Others
By Application
Thalassemia
Sickle Cell Anaemia
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Sickle Cell Anemia Anticipated to Grow at Significant Rate

  • Sickle cell anemia refers to the group of blood disorders that cause misshape of red blood cells. This makes difficult for RBC to carry oxygen to different organs and tissues. Poor oxygen in the blood may lead to severe pain syndromes, necrosis and bacterial infections.
  • The growing number of cases with sickle cell anaemia globally, coupled with the presence of a robust pipeline of drugs for the treatment of disease is anticipated to boost the segment growth over the forecast period.
  • Drugs used for symptoms of hemoglobinopathies treatment include antibiotics, analgesics, ACE inhibitors. Further, Blood transfusion or stem cell therapy is one of the preferred treatments for hemoglobinopathies. Moreover, increasing research on the treatment of hemoglobinopathies such as gene therapies advancing the market growth.
  • The World Health Organization has estimated that each year about 300000 babies are born with a severe form of inherited blood disorders, and 5% of the world population carries trait genes for haemoglobin disorders, mainly, sickle cell anaemia and thalassemia. Thus the growing incidence of hemoglobinopathies coupled with the rise in R&D investment for the development of treatment options expected to boost the market over the forecast period.
Hemoglobinopathies Treatment Market Trends

Europe is Anticipated to Have Significant Growth

Among the regional segments, Europe is anticipated to have significant market growth over the forecast period. The growth is attributed to a high number of hemoglobinopathies cases especially in Mediterranean countries, new product launches and growing awareness regarding the disorder. North America is anticipated to have notable market growth owing to well-established healthcare infrastructure for early diagnosis and treatment of hemoglobinopathies and initiatives by the government and non-government organizations to increase the awareness. 

Hemoglobinopathies Treatment Market Analysis

Competitive Landscape

Global hemoglobinopathies treatment market is moderately fragmented and competitive. Market players are focusing on new product launches, product innovations and geographical expansion. For instance, in May 2017, Sangamo Therapeutics and Pfizer announced a collaboration for the haemophilia A gene therapy. The key market players operating in the market include Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc. EMI Holding, Inc. and Celgene Corporation among others.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Genetic Blood Disorders

      2. 4.2.2 Presence of Robust Pipeline

    3. 4.3 Market Restraints

      1. 4.3.1 Low Awareness Regarding Hemoglobinopathies

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment

      1. 5.1.1 Stem Cell Therapy

      2. 5.1.2 Blood Transfusion

      3. 5.1.3 Iron Chelation Therapy

      4. 5.1.4 Others

    2. 5.2 By Application

      1. 5.2.1 Thalassemia

      2. 5.2.2 Sickle Cell Anaemia

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Sanofi S.A.

      2. 6.1.2 Global Blood Therapeutics, Inc.

      3. 6.1.3 bluebird bio, Inc.

      4. 6.1.4 EMI Holding, Inc.

      5. 6.1.5 Celgene Corporation

      6. 6.1.6 Gamida Cell

      7. 6.1.7 Prolong Pharmaceuticals, LLC.

      8. 6.1.8 Sangamo Therapeutics Inc.

      9. 6.1.9 Silence Therapeutics

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Hemoglobinopathies Treatment Market market is studied from 2018 - 2026.

The Hemoglobinopathies Treatment Market is growing at a CAGR of 7% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc., EMI Holding, Inc., Celgene Corporation are the major companies operating in Hemoglobinopathies Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!